LU92681I2 - Nintédanib, its tautomers and its salts, in particular Nintédanib and its pharmaceutically acceptable salts, in particular Nintédanib Esilate - Google Patents

Nintédanib, its tautomers and its salts, in particular Nintédanib and its pharmaceutically acceptable salts, in particular Nintédanib Esilate

Info

Publication number
LU92681I2
LU92681I2 LU92681C LU92681C LU92681I2 LU 92681 I2 LU92681 I2 LU 92681I2 LU 92681 C LU92681 C LU 92681C LU 92681 C LU92681 C LU 92681C LU 92681 I2 LU92681 I2 LU 92681I2
Authority
LU
Luxembourg
Prior art keywords
nintédanib
salts
esilate
tautomers
pharmaceutically acceptable
Prior art date
Application number
LU92681C
Other languages
French (fr)
Other versions
LU92681I9 (en
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92681(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19949208A external-priority patent/DE19949208A1/en
Priority claimed from DE2000142696 external-priority patent/DE10042696A1/en
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of LU92681I2 publication Critical patent/LU92681I2/en
Publication of LU92681I9 publication Critical patent/LU92681I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU92681C 1999-10-13 2015-03-16 Nintédanib, its tautomers and its salts, in particular Nintédanib and its pharmaceutically acceptable salts, in particular Nintédanib Esilate LU92681I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19949208A DE19949208A1 (en) 1999-10-13 1999-10-13 New 3-(amino-methylene)-2-indolinone derivatives are kinase inhibitors and cell proliferation inhibitors useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis
DE2000142696 DE10042696A1 (en) 2000-08-31 2000-08-31 New 3-(amino-methylene)-2-indolinone derivatives are kinase inhibitors and cell proliferation inhibitors useful e.g. for treating tumors, metastasis, rheumatoid arthritis or psoriasis
PCT/EP2000/009867 WO2001027081A1 (en) 1999-10-13 2000-10-09 6-position substituted indoline, production and use thereof as a medicament

Publications (2)

Publication Number Publication Date
LU92681I2 true LU92681I2 (en) 2015-05-18
LU92681I9 LU92681I9 (en) 2019-01-03

Family

ID=26006858

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92681C LU92681I2 (en) 1999-10-13 2015-03-16 Nintédanib, its tautomers and its salts, in particular Nintédanib and its pharmaceutically acceptable salts, in particular Nintédanib Esilate

Country Status (43)

Country Link
EP (2) EP2157081A1 (en)
JP (2) JP4021664B2 (en)
KR (2) KR100835546B1 (en)
CN (1) CN100455568C (en)
AR (1) AR026036A1 (en)
AT (1) ATE439342T1 (en)
AU (1) AU781939B2 (en)
BE (1) BE2015C018I2 (en)
BG (1) BG65983B1 (en)
BR (1) BRPI0014735B8 (en)
CA (1) CA2387013C (en)
CO (1) CO5261488A1 (en)
CY (2) CY1110067T1 (en)
CZ (1) CZ301073B6 (en)
DE (1) DE50015711D1 (en)
DK (1) DK1224170T5 (en)
EA (1) EA006080B1 (en)
EE (1) EE05427B1 (en)
EG (1) EG25931A (en)
ES (1) ES2331459T3 (en)
FR (1) FR15C0024I2 (en)
HK (1) HK1052505B (en)
HR (1) HRP20020306B1 (en)
HU (2) HU230416B1 (en)
IL (2) IL148756A0 (en)
LT (1) LTC1224170I2 (en)
LU (1) LU92681I2 (en)
ME (1) MEP45408A (en)
MX (1) MXPA02002799A (en)
MY (1) MY127956A (en)
NL (1) NL300725I2 (en)
NO (3) NO322746B1 (en)
NZ (1) NZ518489A (en)
PE (1) PE20010671A1 (en)
PL (1) PL207445B1 (en)
PT (1) PT1224170E (en)
RS (1) RS51013B (en)
SA (1) SA01210704B1 (en)
SI (1) SI1224170T1 (en)
SK (1) SK287312B6 (en)
TW (1) TWI268922B (en)
UA (1) UA75054C2 (en)
WO (1) WO2001027081A1 (en)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816624A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
CN101029022B (en) 2000-10-20 2011-01-12 卫材R&D管理有限公司 Process for producing nitrogen-containing aromatic ring derivative
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (en) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma Indolinones substituted in the 6-position, their preparation and their use as medicaments
PT1401416E (en) 2001-06-29 2007-02-28 Ab Science Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd)
WO2003002109A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
CA2452169A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
CA2452371A1 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
ATE376182T1 (en) 2001-06-29 2007-11-15 Ab Science C-KIT INHIBITORS
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
EP1430048A1 (en) * 2001-09-27 2004-06-23 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
RU2316554C2 (en) 2001-12-27 2008-02-10 Тереванс, Инк. Derivatives of indoline used as protein kinase inhibitors
SE0302546D0 (en) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
ITBO20020198A1 (en) * 2002-04-12 2003-10-13 Univ Bologna DERIVATIVES 2, 5 BIS DIAMMINO 1, 4 BENZOCHENIONIC USEFUL FOR THE TREATMENT OF ALZHEIMER DISEASE, METHOD FOR THEIR PREPARATION AND
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (en) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z- [1- (4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl- 2-indolinone monoethanesulfonate and its use as a medicament
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (en) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (en) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド Kinase inhibitors for the treatment of diseases
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2005044788A1 (en) 2003-11-11 2005-05-19 Eisai Co., Ltd. Urea derivative and process for producing the same
SE0401790D0 (en) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
DE602005013990D1 (en) 2004-09-17 2009-05-28 Eisai R&D Man Co Ltd MEDICAL COMPOSITION WITH IMPROVED STABILITY AND REDUCED GELING PROPERTIES
PE20060777A1 (en) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
JP4989476B2 (en) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for assaying the effects of angiogenesis inhibitors
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
CN104706637A (en) 2006-05-18 2015-06-17 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
KR101472600B1 (en) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Antitumor agent for undifferentiated gastric cancer
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
WO2008152013A1 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
ES2435454T3 (en) 2007-06-21 2013-12-19 Janssen Pharmaceutica, N.V. Indolin-2-one and aza-indolin-2-one
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
PE20091445A1 (en) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int INDOLINONE DERIVATIVES AND PROCEDURE FOR ITS MANUFACTURE
NZ585799A (en) 2007-12-03 2012-04-27 Boehringer Ingelheim Int Process for the manufacture of an indolinone derivative in particular 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
HUE037291T2 (en) 2008-06-06 2018-08-28 Boehringer Ingelheim Int Pharmaceutical combination
TW201011002A (en) * 2008-07-29 2010-03-16 Boehringer Ingelheim Int New compounds
EP2387401A1 (en) 2009-01-14 2011-11-23 Boehringer Ingelheim International GmbH Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
JP2012526766A (en) 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング A novel combination therapy in the treatment of neoplastic and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2011162343A1 (en) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 Antitumor agent using compounds having kinase inhibitory effect in combination
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
AU2013211888B2 (en) 2012-01-26 2017-08-31 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
JP6207625B2 (en) * 2012-12-06 2017-10-04 山東亨利醫藥科技有限責任公司 Indolinone derivatives as tyrosine kinase inhibitors
KR20150098605A (en) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 Amorphous form of quinoline derivative, and method for producing same
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN104003925B (en) * 2013-06-05 2016-03-30 四川大学 Indolinone compound or its derivative and use thereof
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
CA2919498C (en) 2013-07-31 2023-07-25 Windward Pharma, Inc. Aerosol nintedanib compounds and uses thereof
HUE059606T2 (en) 2014-08-28 2022-11-28 Eisai R&D Man Co Ltd High-purity quinoline derivative and method for manufacturing same
CN104262232B (en) * 2014-09-09 2016-05-04 苏州明锐医药科技有限公司 The preparation method of Ni Taidani
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499B (en) * 2015-06-05 2017-03-08 北京康立生医药技术开发有限公司 One kettle way prepares the synthetic method of Nintedanib
CN114010787A (en) 2015-06-06 2022-02-08 拨云生物医药科技(广州)有限公司 Compositions and methods for treating pterygium
JP6757959B2 (en) 2015-06-16 2020-09-23 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ Anti-cancer agent
CN105126909B (en) * 2015-07-13 2018-01-23 淮海工学院 Application of the immobilized palladium catalyst in the synthesis of the nitrobenzene methyl of 4 phenylacetylene base 3
CZ308695B6 (en) 2015-07-29 2021-03-03 Zentiva, K.S. Process for preparing methyl (Z) -3 - [[4- [methyl [2- (4-methyl-1-piperazinyl) acetyl] amino] phenyl] amino] phenylmethylene) -oxindole-6-carboxylate (intedanib, nintedanib)
CN106467500A (en) * 2015-08-14 2017-03-01 廊坊百瑞化工有限公司 A kind of one pot synthesis synthesize the new method of Nintedanib key intermediate
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
LT3722291T (en) * 2015-12-24 2023-12-11 Respivert Limited INDOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF FIBROTIC DISEASES
CZ2016104A3 (en) 2016-02-24 2017-09-06 Zentiva, K.S. Crystalline modifications of methyl (3Z)-3- {[(4-{methyl[(4-methylpiperazin-1yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2oxo-2,3-dihydro-1H-indole-6-carboxylate and the methods of their preparation
BR112018068213A2 (en) 2016-03-08 2019-01-29 Respivert Ltd indole derivatives and their use as protein kinase inhibitors
EP3442534A1 (en) 2016-04-13 2019-02-20 Boehringer Ingelheim International GmbH Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
US20190275032A1 (en) 2016-05-27 2019-09-12 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for determining the treatment onset with nintedanib and pirfenidone
WO2017207643A1 (en) 2016-06-01 2017-12-07 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone
CN119656170A (en) 2016-06-02 2025-03-21 拨康视云生物医药科技(广州)有限公司 Compositions and methods for treating ocular diseases with aberrant neovascularization using nilamide
CN114569606B (en) 2016-07-29 2024-04-19 英克特诺治疗公司 Uses of indolinone compounds
CN106748961A (en) * 2016-11-30 2017-05-31 瑞阳制药有限公司 The impurity compound of Nintedanib, preparation method, using and its detection method
CN106748960A (en) * 2016-11-30 2017-05-31 瑞阳制药有限公司 The potential impurity compound of Nintedanib, preparation method, using and its detection method
EP3551187B1 (en) 2016-12-12 2021-02-17 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
BR112019014127A2 (en) 2017-02-08 2020-02-11 Eisai R&D Management Co., Ltd. PHARMACEUTICAL COMPOSITION FOR TUMOR TREATMENT
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
MX2019013014A (en) 2017-05-16 2020-08-06 Eisai R&D Man Co Ltd Treatment of hepatocellular carcinoma.
IL273169B2 (en) 2017-10-23 2024-05-01 Boehringer Ingelheim Int A new combination of active substances for the treatment of advanced lymphoid interstitial lung diseases
CA3082714A1 (en) 2017-11-17 2019-05-23 Fermion Oy Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib
JP7061310B2 (en) * 2018-04-05 2022-04-28 国立大学法人 大分大学 Pharmaceuticals for the prevention and treatment of chronic fatty diseases
CN108358827A (en) * 2018-05-07 2018-08-03 日照市普达医药科技有限公司 It is a kind of to treat psoriasic 2- oxo-indoles analog derivative and preparation method thereof
EP3813793B1 (en) 2018-05-25 2023-09-20 ADS Therapeutics LLC A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
PE20211054A1 (en) * 2018-10-05 2021-06-07 Ichnos Sciences S A INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS
JP2023519600A (en) 2020-04-01 2023-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of biomarkers in treating fibrotic conditions
CN111848490B (en) * 2020-08-24 2021-09-24 江西国药有限责任公司 A kind of preparation method of high-purity nintedanib ethanesulfonate
CN112574094B (en) * 2020-12-14 2022-07-01 成都大学 Indolinone derivatives and their pharmaceutical uses
EP4282874A4 (en) 2021-01-25 2024-08-28 Nibec Co., Ltd. PEPTIDE TO PREVENT AND TREAT FIBROSIS
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
CN115703758B (en) * 2021-08-12 2024-03-26 中国医学科学院药物研究所 A class of compounds used as kinase inhibitors and preparation methods and uses thereof
EP4572763A1 (en) 2022-08-16 2025-06-25 Boehringer Ingelheim International GmbH Pharmaceutical formulations of nintedanib for intraocular use
TWI857798B (en) * 2023-09-28 2024-10-01 國立臺灣大學 Indoline derivatives for treatment and/or prevention of tumor or cell proliferative and fibrosis diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558210A (en) * 1956-06-08
AU684950B2 (en) * 1994-05-06 1998-01-08 Alcon Laboratories, Inc. Use of vitamin E tocopheryl derivatives in ophthalmic compositions
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ATE243034T1 (en) * 1996-01-17 2003-07-15 Taiho Pharmaceutical Co Ltd INTIMAL THICKENING INHIBITORS
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (en) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma New substituted indolinones, their production and their use as medicines
DE19816624A1 (en) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
DE19824922A1 (en) * 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Novel substituted indolinones, their preparation and their use as pharmaceuticals
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
LTC1224170I2 (en) 2023-11-10
HK1052505B (en) 2009-06-26
CY2015009PI2 (en) 2016-12-14
DK1224170T3 (en) 2009-12-07
CZ20021410A3 (en) 2002-07-17
JP2007302697A (en) 2007-11-22
CN100455568C (en) 2009-01-28
SA01210704B1 (en) 2006-12-05
HK1052505A1 (en) 2003-09-19
BRPI0014735B1 (en) 2012-07-10
MEP45408A (en) 2011-02-10
SK6462002A3 (en) 2002-08-06
FR15C0024I2 (en) 2016-08-26
HUP0204587A2 (en) 2003-05-28
HUS1600022I1 (en) 2017-02-28
ES2331459T3 (en) 2010-01-05
IL148756A (en) 2007-10-31
JP2003511441A (en) 2003-03-25
HUP0204587A3 (en) 2004-07-28
KR20070095996A (en) 2007-10-01
PT1224170E (en) 2009-10-01
BG106587A (en) 2003-01-31
CN1391557A (en) 2003-01-15
UA75054C2 (en) 2006-03-15
HRP20020306A2 (en) 2003-10-31
NZ518489A (en) 2005-05-27
KR20020038949A (en) 2002-05-24
NL300725I2 (en) 2017-07-13
CY1110067T1 (en) 2015-01-14
BG65983B1 (en) 2010-08-31
FR15C0024I1 (en) 2015-04-17
BRPI0014735A (en) 2002-07-16
AR026036A1 (en) 2002-12-26
HRP20020306B1 (en) 2010-09-30
NO322746B1 (en) 2006-12-04
TWI268922B (en) 2006-12-21
CA2387013A1 (en) 2001-04-19
EE05427B1 (en) 2011-06-15
MY127956A (en) 2007-01-31
NO20021719D0 (en) 2002-04-11
YU26602A (en) 2004-11-25
EP1224170B1 (en) 2009-08-12
RS51013B (en) 2010-10-31
EP1224170B9 (en) 2017-11-22
EA200200380A1 (en) 2002-10-31
HU230416B1 (en) 2016-05-30
AU781939B2 (en) 2005-06-23
PE20010671A1 (en) 2001-06-28
CO5261488A1 (en) 2003-03-31
CA2387013C (en) 2009-12-29
NO2015009I2 (en) 2015-03-18
MXPA02002799A (en) 2003-02-27
LU92681I9 (en) 2019-01-03
IL148756A0 (en) 2002-09-12
LTPA2015015I1 (en) 2015-04-27
SK287312B6 (en) 2010-06-07
KR100857734B1 (en) 2008-09-10
SI1224170T1 (en) 2009-12-31
CZ301073B6 (en) 2009-10-29
EE200200197A (en) 2003-06-16
AU1023301A (en) 2001-04-23
EG25931A (en) 2012-10-24
PL355433A1 (en) 2004-04-19
NO2023033I1 (en) 2023-09-05
CY2015009PI1 (en) 2016-12-14
NO20021719L (en) 2002-04-11
NO2015009I1 (en) 2015-03-30
EA006080B1 (en) 2005-08-25
PL207445B1 (en) 2010-12-31
EP2157081A1 (en) 2010-02-24
JP4021664B2 (en) 2007-12-12
WO2001027081A1 (en) 2001-04-19
ATE439342T1 (en) 2009-08-15
DE50015711D1 (en) 2009-09-24
BE2015C018I2 (en) 2019-10-23
DK1224170T5 (en) 2018-01-22
BRPI0014735B8 (en) 2021-07-06
EP1224170A1 (en) 2002-07-24
KR100835546B1 (en) 2008-06-09

Similar Documents

Publication Publication Date Title
LU92681I2 (en) Nintédanib, its tautomers and its salts, in particular Nintédanib and its pharmaceutically acceptable salts, in particular Nintédanib Esilate
LU91501I2 (en) Sugammadex and its pharmaceutically acceptable salts-BRIDION
LU92182I2 (en) Dapagliflozin and its pharmaceutically acceptable salts
LU91280I2 (en) Sorafenib and pharmaceutically acceptable salts
LU91363I2 (en) Methoxy polyethylene glycol-epoetin beta and its pharmaceutically acceptable salts (MIRCERA)
LU91650I2 (en) Saxagliptin and pharmaceutically acceptable salts thereof, including saxagliptin hydrochloride - Onglyza-saxagliptin
LU92381I2 (en) Macitentan and its pharmaceutically acceptable derivatives (OPSUMIT)
ATE443052T1 (en) BACTERIAL GYRASE INHIBITORS AND THEIR USE
NO2011002I1 (en) Regadenosone and its salts.
LU91076I2 (en) Tulathromycin and its pharmaceutically acceptable salts (draxxin).
DK1177178T3 (en) Heterocyclic substituted benzimidazoles, their preparation and use
MXPA03005923A (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines.
NO2008001I1 (en) Vildagliptin and pharmaceutically acceptable salts thereof
ZA200202479B (en) Heterocyclic sodium/proton exchange inhibitors and method.
NO20025227L (en) Tropane derivatives useful in therapy
MXPA03005713A (en) Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors.
PL356427A1 (en) Indol-3-yl derivatives and their use as integrin inhibitors
LU91345I2 (en) Rufinamide and its pharmaceutically acceptable salts (inovelon)
ZA200207489B (en) Apomorphine derivatives and methods for their use.
AU5066900A (en) Benzimidazole derivatives and their use as methionyl t-rna synthetase inhibitors
NO2005007I2 (en) Pemetrexed and pharmaceutically acceptable salts thereof
IL146629A0 (en) Indolylpiperidine derivatives as antihistaminic and antiallergic agents
NO20024598D0 (en) Pharmaceutically active pyrrolidine derivatives
NO20016419L (en) Melagatran in substantially crystalline form
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors